bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

1
2

Sex Differences in Oncogenic Mutational
Processes

3
4
5
6

Constance H. Li1,2, Stephenie D. Prokopec1, Ren X. Sun1,3, Fouad Yousif1, Nathaniel Schmitz1,
Paul C. Boutros1,2,3,4,5,6,7,8, for the PCAWG Molecular Subtypes and Clinical Correlates Working
Group, ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Network

7
8

1

Ontario Institute for Cancer Research, Toronto, Ontario, Canada

9

2

Department of Medical Biophysics, University of Toronto; Toronto, Ontario, Canada

10

3

Department of Pharmacology & Toxicology, University of Toronto; Toronto, Ontario, Canada

11

4

12

5

Department of Human Genetics, University of California, Los Angeles, CA, USA

13

6

Department of Urology, University of California, Los Angeles, CA, USA

14

7

Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA

15

8

Institute for Precision Health, University of California, Los Angeles, CA, USA

Vector Institute for Artificial Intelligence, Toronto, Canada

16
17

Correspondence should be addressed to P.C.B. (PBoutros@mednet.ucla.edu)

18
19
20
21
22

12-109 CHS
10833 Le Conte Avenue
Los Angeles, CA, 90095
Phone: 310-794-7160

23
24

Abstract

25
26
27
28
29
30
31
32
33
34

Sex differences have been observed in multiple facets of cancer epidemiology, treatment and
biology, and in most cancers outside the sex organs. Efforts to link these clinical differences to
specific molecular features have focused on somatic mutations within the coding regions of the
genome. Here, we describe the first pan-cancer analysis of sex differences in whole genomes of
1,983 tumours of 28 subtypes from the ICGC Pan-Cancer Analysis of Whole Genomes project.
We both confirm the results of exome studies, and also uncover previously undescribed sex
differences. These include sex-biases in coding and non-coding cancer drivers, mutation
prevalence and strikingly, in mutational signatures related to underlying mutational processes.
These results underline the pervasiveness of molecular sex differences and strengthen the call
for increased consideration of sex in cancer research.

Page 1 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

35
36
37
38
39
40
41
42
43

Sex disparities in cancer epidemiology include an increased overall cancer risk in males
corresponding with higher incidence in most tumor types, even after adjusting for known risk
factors1,2. Cancer mortality is also higher in males, due in part to better survival for female patients
in many cancer types, including those of the colon and head & neck3. Interestingly, female
colorectal cancer patients respond better to surgery4 and adjuvant chemotherapy, though this is
partially due to biases in tumour location and microsatellite instability5. Similarly, premenopausal
female nasopharyngeal cancer patients have improved survival regardless of tumour stage,
radiation or chemotherapy regimen6. There is a growing body of evidence for sex differences in
cancer genomics7-13, but their molecular origins and clinical implications remain largely elusive.

44
45
46
47
48
49
50
51
52
53
54

Previous studies have mostly focused on protein coding regions, leaving the vast majority of the
genome unexplored. We hypothesized that there are uncharacterized sex differences in the noncoding regions of the genome. Using whole genome sequencing data from the Pan-cancer
Analysis of Whole Genomes (PCAWG) project14, we performed a survey of sex-biased mutations
in 1,983 samples (1,213 male, 770 female) from 28 tumour subtypes, excluding those of the sex
organs (Supplementary Table 1). We also excluded the X and Y chromosomes to focus on
autosomal sex differences in cancers affecting both men and women, but there are known to be
significant X-chromosome mutational differences between tumours arising in men and women15.
Our analysis revealed sex differences in both genome-wide phenomena and in specific genes.
These sex-biases occur not only at the pan-cancer level across all 1,983 samples, but also in
individual tumour subtypes.

55
56
57
58
59
60
61
62
63
64
65
66

Sex-biases in driver genes, mutation load and tumour evolution

67
68
69
70
71
72
73
74
75
76
77

We also identified tumour subtype-specific sex-biased driver mutations (Figure 1a, right).
Similarly to the pan-cancer driver analysis, we first identified putative sex-biases using proportions
tests and a 10% FDR threshold, and followed up with tumour subtype-specific logistic regression
models (model descriptions in Supplementary Table 1). CTNNB1 mutation frequency was sexbiased in liver hepatocellular cancer (Liver-HCC), again with more male-derived samples
harbouring CTNNB1 mutations: (male: 31%, female: 13%, 95% CI: 8.1-28%, prop-test q = 0.047,
LGR q = 8.2x10-3, Figure 1a, right). This mirrors our previous finding of sex-biased CTNNB1
mutation frequency in liver cancer from TCGA exome sequencing data, with similar effect sizes
(male: 33% vs. female: 12%11). The largest sex-disparity was in a non-coding driver event in
thyroid cancer (Thy-AdenoCA): TERT promoter mutations were observed in 64% of male-derived
samples compared with only 11% of female-derived samples (95% CI: 18-89%, prop-test q =

We began by investigating sex differences in driver gene mutation frequencies, focusing on 165
coding and nine non-coding mutation events16 (Supplementary Table 2). We used proportions
tests to identify candidate sex-biased events with a false discovery rate (FDR) threshold of 10%.
These putative sex-biased events were then modeled using logistic regression (LGR) to adjust
for tumour subtype, ancestry and age (Online Methods). We found several sex-biased pancancer driver events, including CTNNB1 which was mutated in 5.0% more male-derived than
female-derived tumours (male: 7.6%, female: 2.7%, 95% CI: 2.9-7.0%, prop-test q = 3.6x10-4,
LGR q = 5.0 x 10-3; Figure 1a, left). ALB was also mutated in a larger proportion of male-derived
tumours (male: 3.2%, female: 0.54%, 95% CI: 1.4-3.9%, prop-test q = 0.0038, LGR q = 6.5 x 103
) while in contrast, PTCH1 (male: 0.44%, female: 2.0%, 95% CI: 0.38-2.8%, prop-test q = 0.028,
LGR q = 0.011) was mutated in more female-derived samples.

Page 2 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

78
79
80
81
82

6.9x10-3, LGR q = 0.074, Figure 1a, right), again supporting a previous finding17. Other putative
sex-biased events were detected, but were not statistically significant after multivariate
adjustment at present sample-sizes (Supplementary Table 2). These results demonstrate that
mutation of key cancer-driving genes is sex-biased both within and across specific tumour
subtypes.

83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101

Our previous work12 found sex biased mutation density across a number of tumour subtypes,
including cancers of the liver, kidney and skin. We therefore investigated mutation density here
to identify tumour subtypes where the cancer genomes of one sex accumulates more somatic
single nucleotide variants (SNVs) than those of the other sex, and whether these sex-biases might
be related to sex-biased driver gene mutation frequency. Returning to our statistical framework,
we first used univariate tests to identify putative sex-biases, and then applied multivariate linear
regression (LNR) on Box-cox transformed mutation load to adjust for possible confounders. The
Box-cox transformation applies a power function to modify the shape of a variableâ€™s distribution
to better approximate a normal distribution (Online Methods). We also compared the total
number of somatic SNVs and further divided mutations by coding and non-coding SNVs to
determine whether sex-biases may be influenced by specific genomic contexts. Across all pancancer samples, we found higher mutation prevalence in male-derived samples in all three
contexts (coding: difference in location = 0.41 mut/Mbp, 95% CI = 0.28-0.54 mut/Mbp, u-test q =
2.2x10-10, LNR q = 7.5x10-4; non-coding: difference in location = 0.60 mut/Mbp, 95%CI = 0.430.80 mut/Mbp, u-test q = 7.9x10-11, LNR q = 6.5x10-4; overall: difference in location = 0.60
mut/Mbp, 95%CI = 0.42-0.79 mut/Mbp, u-test q = 7.5x10-11, LNR q= 1.9 x 10-6; Supplementary
Table 3). These sex-biases remained significant even after adjusting for tumour subtype, ancestry
and age in multivariate analysis (Figure 1b, left), demonstrating robust sex-biases in pan-cancer
mutation prevalence across different contexts.

102
103
104
105
106
107
108
109
110
111
112
113
114
115

We also investigated somatic SNV burden in each of the 23 individual tumour subtypes with at
least 15 samples, applying the same statistical approach with tumour subtype-specific models
(model descriptions in Supplementary Table 1). We found sex-biased mutation load in three
tumour subtypes (Figure 1b, right), with higher male coding mutation load in thyroid cancer
(difference in location = 0.26 mut/Mbp, 95%CI = 0.12-0.43 mut/Mbp, u-test q = 0.028, LNR q =
0.041), and higher male load in hepatocellular cancer and kidney renal cell cancer (Kidney-RCC)
in all three contexts (Supplementary Table 3). We compared the group rank differences of
coding and non-coding mutation load between the sexes and found that in renal cell cancer, the
differences were similar at 0.40 mut/Mbp for non-coding mutations and 0.37 mut/Mbp for coding
mutations. In hepatocellular cancer however, the median sex-difference in non-coding mutation
load was higher than the difference in coding mutation load (non-coding difference = 0.84
mut/Mbp vs. coding difference = 0.53 mut/Mbp). There is a similar effect in pan-cancer mutation
load (non-coding difference = 0.60 mut/Mbp vs coding difference = 0.41 mut/Mbp) suggesting
mutation context may play a role in sex-biased SNVs in some tumour subtypes.

116
117
118
119
120

To determine whether sex-biased mutation load may be associated with sex-biased driver gene
mutation frequency, we focused on each driver gene and investigated SNV burden in the relevant
tumour subtype. We did not find significant relationships between SNV burden and mutations in
PTCH1, ALB, CTNNB1 in pan-cancer analysis, nor was there an association for CTNNB1
mutation in hepatocellular cancer. In thyroid cancer however, TERT promoter mutation was
Page 3 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

121
122
123
124
125
126
127
128

associated with increased coding mutation burden (medianTERT-wt = 0.26 mut/Mbp vs medianTERT-6
mut = 0.66 mut/Mbp, u-test p = 4.9x10 ). We used a linear regression model to determine if the
sex-bias in coding mutation load could be explained by TERT mutation frequency and found this
was indeed the case (linear regression pTERT = 2.4x10-5, psex = 0.37, Figure 1c). In addition, we
examined matched mutation timing data and found that of eleven samples with TERT promoter
mutations, nine of these were truncal events, suggesting that an early sex-bias in TERT promoter
mutation frequency is associated with sex-biased coding mutation load in this tumour subtype.
Indeed, mutations in all sex-biased driver genes were overwhelmingly truncal events.

129
130
131
132
133
134
135
136
137
138
139
140
141

We then asked if these driver mutations might occur at different stages of tumour evolution
between men and women, and started with tumour evolution structure. We compared the
proportions of polyclonal vs. monoclonal tumours between the sexes and did not find significant
sex differences in the proportions of polyclonal tumours bearing mutations in PTCH1, ALB or
CTNNB1 for sex-biased pan-cancer drivers, or in TERT promoter-mutated samples in thyroid
cancer (Supplementary Figure 1). We did detect a putative bias in the proportion of polyclonal
CTNNB1-mutated samples in hepatocellular cancer (80% of male-derived samples are polyclonal
vs. 46% of female-derived samples, 95%CI = -0.019 â€“ 0.70, prop-test p = 0.039), and accounted
for polyclonality when comparing the timings of the mutations in these driver events. On
subsequently examining the frequency of clonal vs. subclonal driver mutation events between the
sexes, we found that while there were differences in the proportions of truncal mutations (eg:
100% of TERT promoter mutations were truncal events in male-derived vs. 50% truncal events in
female-derived thyroid cancer patients), no comparisons were statistically significant.

142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160

Broadening beyond sex-biased driver mutations, we expanded our clonality analysis to perform
a general survey of clonal structure and mutation timing across all tumour subtypes and mutations
(Supplementary Table 4). We found that female-derived biliary adenocarcinoma (BiliaryAdenoCA) tumours were frequently polyclonal, while most male-derived tumours were
monoclonal (26% male-derived samples are polyclonal vs. 80% female-derived, 95% CI = 19 â€“
88%, prop-test q = 0.063, LGR q = 0.024; Figure 1d). In addition, we found intriguing evidence
suggesting there may be sex-differences in the mutation timing of structural variants in this tumour
subtype. Structural variants (SVs) in male-derived samples tended to be truncal events more
frequently than in female-derived samples (median male percent truncal SVs = 100% vs. median
female = 82%, u-test q = 0.081, LNR q = 0.024; Figure 1e). Though other comparisons did not
reach our statistical significance threshold, we found some interesting trends that may merit future
study, including in esophageal cancer (Eso-AdenoCA) where SVs in female-derived samples
were more frequently truncal events while SVs in male-derived samples occurred more frequently
in subclones (median male percent truncal SVs = 55%, median female = 100%; Supplementary
Figure 2), and in medulloblastoma, where insertion-deletions (indels) were more frequently
truncal events in female-derived samples than male (median male percent of truncal indels =
65%, median female proportion of truncal indels = 70%; Supplementary Figure 3). Our analysis
of sex differences in tumour evolution identified some sex-biased events and also hint at putative
sex-biases that should be further explored in future analyses.

161
162
163

Sex-biases in genome instability and CNAs
Next, we examined percent genome altered (PGA), which provides a summary of copy number
aberration (CNA) load. A proxy for genome instability, PGA is a complementary measure of
Page 4 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

164
165
166
167
168
169
170
171
172
173
174
175

mutation density to somatic SNV burden. While we did not find associations between sex and
autosome-wide PGA, we observed sex-biases in the copy number burden for specific
chromosomes (Figure 2a). In pan-cancer analysis, male-derived samples exhibited a slight but
significant higher percent chromosome altered for chromosome 7 even after accounting for
tumour subtype, ancestry and age using linear regression (median male PGA-7 = 5.4%, median
female PGA-7 = 0.37%, difference in location = 0.0037%, 95%CI = 9.4x10-4â€“2.4x10-3%, u-test =
5.0x10-3, LNR q = 0.027; Supplementary Table 5). In individual tumour subtypes, we found sexbiased PGA in renal cell cancer (chromosomes 7 & 12) and hepatocellular cancer (chromosomes
1 & 16). By looking at copy number gains and losses separately, we additionally identified
chromosomes with sex-biases in the burden of copy number gains and losses (Supplementary
Figure 4, Supplementary Table 5), including sex-biased percent copy gained on chromosomes
5, 8 and 17 in pan-cancer samples.

176
177
178
179
180
181
182
183
184
185
186
187

We next compared CNA frequency on the gene level to identify genes lost or gained at sex-biased
rates. Across all pan-cancer samples, we found 4,285 sex-biased genes across 15 chromosomes
(Figure 2b, Supplementary Tables 6 & 7, LGR q-value < 10%). These genes were all more
frequently gained in male-derived samples than female with a difference in copy number gain
frequency reaching ~10% on chromosomes 7 and 8. Genes with male-dominated copy number
gains include the oncogenes MYC (male gain frequency = 37% vs. female gain frequency = 28%,
95% CI = 5.2-14%, prop-test q = 2.5x10-3, LGR q = 0.068) and ERBB2 (male gain frequency =
21% vs. female gain frequency = 16%, 4.7%, 95% CI = 1.1-8.3%, prop-test q = 0.041, LGR q =
0.088). The driver CTNNB1 was also more frequently gained in male samples (male gain
frequency = 8.9% vs. female gain frequency = 5.2%, 95% CI = 1.4-6.1%, prop-test q = 0.016,
LGR q = 0.053), mirroring our finding of higher male pan-cancer mutation frequency on the SNV
level for this oncogene. We did not find pan-cancer sex-biased copy number losses.

188
189
190
191
192
193
194
195
196
197
198
199
200
201
202

We repeated this analysis for every tumour subtype independently and found sex-biased CNAs
in renal cell and hepatocellular cancer (Supplementary Tables 6 & 7). In renal cell cancer, the
1,986 sex-biased gains all occurred more frequently in male-derived samples, with differences in
frequency up to 35% (Figure 2c). They spanned across chromosomes 7 and 12, agreeing with
our finding of male-dominated genome instability in these chromosomes (Figure 2a,
Supplementary Figure 4). In contrast to the male-dominated gain pan-cancer and renal cell
findings, we found higher female frequency of copy number losses in hepatocellular cancer
(Figure 2d). We identified 2,610 genes with higher copy number loss rates in female-derived
samples. As observed in renal cell cancer, some of these losses span whole chromosomes, in
this case chromosomes 3 and 16. Other sex-biased losses were found only across one
chromosome arm (1p, 4q) or as focal events (eg. PCDH9 on chromosome 13). The sex-biased
gene-level events on chromosomes 1 and 16 agreed with the sex-biased genome instability
findings but on returning to the PGA analysis, we found that chromosomes 3 and 4 had trending
sex-biased genome instability (u-test q < 0.2, Figure 1a, Supplementary Table 5), suggesting
that sex-biased PGA may guide identification of sex-biased CNAs on the gene level.

203
204
205
206

Thus, using sex-biased PGA as a guide, we more closely examined regions of interest in tumour
subtypes of that did not have sex-biased CNAs in our general CNA analysis, but did have possible
sex-biased genome instability (u-test q < 0.2): biliary cancer, B-cell non-Hodgkin lymphoma
(Lymph-BNHL), chronic lymphocytic leukemia (Lymph-CLL) and melanoma (Skin-Melanoma).
Page 5 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

207
208
209
210
211
212
213
214

We found an additional 203 genes on the p-arm of chromosome 8 that were more frequently lost
in female-derived samples in biliary cancer (Supplementary Figure 5). These copy number
losses were 50% more common in female-derived samples and affect genes such as DLC1, a
known tumour suppressor in hepatocellular cancer that is thought to play a similar role in
gallbladder cancer18. While we did not identify additional sex-biased CNAs in non-Hodgkin
lymphoma, chronic lymphocytic leukemia or melanoma, the sex-biased PGA results suggest
these as regions of interest for future work. Thus in addition to sex-biased SNV events, we also
identified sex-biased CNAs from this whole genome sequencing data.

215
216
217
218
219
220
221
222
223
224
225
226
227

Sex biases in mutation signatures

228
229
230
231
232
233
234
235
236
237
238
239
240

At the pan-cancer level, we found eight signatures that occurred more frequently in one sex over
the other (Figure 3a, Supplementary Table 8). In particular, SBS1 was more common in femalederived samples (89% of male-derived vs. 97% of female-derived, Ï‡2-test q = 3.9x10-10, LGR q =
5.1x10-7) and was also associated with a higher percentage of mutations in these samples (male
median percent mutations attributed to SBS1 = 8.4%, female median = 10%, u-test q =0.026,
LNR q = 0.021). SBS1 is thought to be caused by deamination of 5-methylcytosine to thymine,
resulting in base substitutions. Though it is correlated with age, our multivariate model accounts
for this variable and the sex-bias remains even adjusting for age. SBS40 was also detected in a
larger proportion of female-derived samples (42% of male-derived vs. 52% of female-derived, Ï‡2test q = 1.7x10-4, LNR q = 0.08), though we did not find a difference in the percentage of attributed
mutations (u-test q = 0.17). Other sex-biased SBS signatures include SBS16, SBS17a and
SBS17b, which were all more frequently detected in male-derived samples, and SBS40, which
was more frequent in female-derived samples. These signatures are of unknown aetiology.

241
242
243
244
245
246
247
248

One ID signature was detected at different rates between the sexes, and two ID signatures had
different rates of attributed mutations. ID8 occurred more frequently in male-derived samples
(53% of male-derived vs. 47% of female-derived, Ï‡2-test q = 0.068, LGR q = 0.018) though there
was no difference in the percentage of mutations attributed to either signature. The aetiology
underlying ID8 is not known, but this signature is thought to be associated with double strand
break repair where ID8-asosciated mutations resemble those related to radiation-induced
damage. Conversely, ID1 and ID5 were detected at similar frequencies between the sexes, but
had higher percentages of attributed mutations in female-derived samples. Mutations associated

We hypothesized that sex differences in mutation load and tumour evolution characteristics may
be driven by varying mutational processes. In addition to single base substitution (SBS)
signatures, which have been well annotated and linked to tumour aetiology19,20, we also examined
doublet base substitution (DBS) and small insertion-deletion (ID) signatures. Sex differences in a
mutational signature could shine insight on molecular differences between the sexes. For each of
47 validated PCAWG SBS, 11 DBS, and 17 ID signatures21, we performed a two-stage analysis.
We first compared the proportions of signature-positive samples between the sexes; that is, we
looked at the proportions of samples with any mutations attributed to the signature to determine
whether there was a relationship between each signature and sex. Then, we focused on
signature-positive samples and compared the percentage of mutations attributed to each
signature between the sexes. For both analyses, we used univariate techniques to identify
putative events and adjusted for additional variables using linear models.

Page 6 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

249
250
251
252

with ID1 are thought to result from slippage during DNA replication and are associated with
defective DNA mismatch repair, suggesting that while male- and female-derived tumours harbour
defective DNA repair at similar rates, it is responsible for a larger proportion of mutations in
female-derived tumours.

253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275

Since mutational processes are disease-specific, we repeated the mutational signatures analysis
in each tumour subtype, again by first using univariate techniques to find putatively sex-biased
signatures, and then using linear models to adjust for age and ancestry. We identified six sexbiased signatures in hepatocellular cancer (Figure 3b, Supplementary Table 8). Similar to our
pan-cancer finding, we again detected female-dominated bias in the proportion of SBS1-positive
samples (58% of male-derived vs. 88% of female-derived, Ï‡2-test q = 3.5x10-5, LGR q = 9.2x10-6)
male-dominated bias in and SBS16 (16% of male-derived vs. 2.2% of female-derived, Ï‡2 q =
9.6x10-3, LGR q = 6.4x10-3). There were four sex-biased ID signatures in this tumour subtype: ID3
(94% of male-derived vs. 81% of female-derived, Ï‡2-test q = 5.2x10-3, LGR q = 3.8x10-3), ID8
(93% of male-derived vs. 78.7% of female-derived, Ï‡2-test q = 3.7x10-3, LGR q = 3.8x10-3) and
ID11 (17% of male-derived vs. 1.1% of female-derived, Ï‡2-test q = 3.7x10-3, LGR q = 6.4x10-3)
occurred more frequently in male-derived samples. While ID1 was detected at similar rates
between the sexes, a greater proportion of ID1-attributed mutations were found in female-derived
than male-derived samples (male median percent mutations attributed to ID1 = 21%, female
median = 27%, u-test q = 2.0x10-5, LR q = 2.2x10-6). As previously described, SBS1 and ID1 are
associated with base deamination and defective DNA mismatch repair. ID3 is associated with
tobacco smoke, and ID8 with double-stranded break repair. Taken together, sex-biases in the
aetiology underlying the molecular landscape of hepatocellular cancer begin to emerge. In this
tumour subtype, spontaneous or enzymatic deamination of 5-methylcytosine to thymine and
defective mismatch repair occur more frequently in female patients and are also responsible for
more mutations. Conversely, tobacco smoking is more common in male patients though the
number of mutations attributed to tobacco smoke is not different between the sexes; this leads to
more tobacco-associated male hepatocellular tumours.

276
277
278
279
280
281
282
283
284
285
286
287
288
289

In B-cell non-Hodgkin lymphoma, we identified a significant difference in the proportion of samples
with SBS17b-attributed mutations (Figure 3c, Supplementary Table 8). More male-derived
samples had mutations associated with this signature of unknown aetiology (57% of male-derived
vs. 25% of female-derived, Ï‡2-test q = 0.051, LGR q = 6.3x10-4). There were also several intriguing
sex-differences in mutational signatures that did not meet our significance threshold. For instance,
DBS2 accounts for a higher percentage of mutations in male-derived samples (male median
percent mutations attributed to DBS2 = 50%, female median = 33%, Supplementary Table 8).
DBS2â€™s association with tobacco smoking suggests that future insight in this signature may
provide molecular explanations for the sex-specific associations between smoking and thyroid
cancer risk22. As the aetiologies of these mutational signatures become better known, we can
better approach the causes of molecular sex differences underlying cancer aetiology and
progression. In particular, we may be able to discern environmental and lifestyle factors even in
the absence of reported data, and connect known risk factors with newly described mutational
processes.

290
291

Finally, to ensure that our findings were not skewed by differences in sequencing quality, we
checked for sex-biases in quality control (QC) metrics. These included comparing the coverage,
Page 7 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

292
293
294
295
296
297
298
299
300
301
302

percentage of paired reads mapping to different chromosomes, and overall quality summary of
both tumour and normal genomes. We mirrored our main analyses and used u-tests or Ï‡2 tests
and linear modeling to check each QC metric. We did not find sex-biases in any QC metric in pancancer or tumour subtype analysis after multiple adjustment except in raw somatic mutation
calling (SMC) coverage. SMC coverage was higher in male-derived samples in six tumour
subtypes including thyroid cancer and esophageal cancer, and was higher in female-derived
samples in lung adenocarcinoma and B-cell non-Hodgkin lymphoma (Supplementary Table 9).
While we do not find sex differences in comparing the SMC coverage pass/fail rates using a
recommended minimum of 2.6 gigabases covered, it is prudent to consider sex-biased SMC in
relation to our findings. There are also no sex-differences in the proportions of samples passing
quality checks for any other QC metric (Supplementary Table 9, Supplementary Figures 6).

303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321

Our analysis of whole genome sequencing data from the PCAWG project uncovered sex
differences in the largely unexplored non-coding autosomal genome. We found these biases in
measures of mutational load, tumour evolution, mutational signatures, and at the gene level.
While the majority of our findings describe pan-cancer differences, we have also uncovered an
intriguing glimpse into tumour subtype-specific differences. These tumour subtype-specific results
are limited by subtype sample size, and limited available annotation restricts the ability to account
for confounding variables. It is important to consider these results in context of the multivariable
models used, which do not directly capture characteristics such as tobacco smoking history or
tumour stage at diagnosis. Future increases in sample size and robust associated annotation will
allow for the detection of smaller effects and the control of more confounders. Nevertheless, our
analyses of driver genes and copy number alterations suggest functional impacts of genomic sexbiases on the transcriptome and tumorigenesis. By using signatures to distinguish between
mutations attributed to lifestyle factors such as smoking, we can better describe sex differences
related to biological factors such as hormone activity. And despite low tumour subtype-specific
sample numbers, our mutation timing and mutational signatures findings at both the pan-cancer
and tumour-subtype level hint at underlying mutational processes that may give rise to molecular
sex-biases. Combined with our previous work in whole exome sequencing, we present a
landscape of sex-biases in cancer genomics and mutational processes (Figure 4,
Supplementary Figure 7).

322
323
324
325
326
327
328

It is becoming clear that sex differences occur across many mutation classes and the portrait of
differences for each tumour subtype is a unique reflection of active mutational processes and
tumour evolution. We have performed here the first pan-cancer analysis of sex differences in
whole genome sequencing data and catalogued previously undescribed sex-biases. However,
increased study of molecular sex differences in future large-scale sequencing efforts is needed
to strengthen the findings we present here, to determine why men and women have molecularly
different tumours, and to determine how this information can be leveraged to improve patient care.

Page 8 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

329

Acknowledgments

330
331
332
333
334
335
336
337
338
339
340

The authors thank all the members of the Boutros lab for insightful discussions. This study was
conducted with the support of the Ontario Institute for Cancer Research to P.C.B. through funding
provided by the Government of Ontario. This work was supported by the Discovery Frontiers:
Advancing Big Data Science in Genomics Research program, which is jointly funded by the
Natural Sciences and Engineering Research Council (NSERC) of Canada, the Canadian
Institutes of Health Research (CIHR), Genome Canada and the Canada Foundation for
Innovation (CFI). P.C.B. was supported by a Terry Fox Research Institute New Investigator Award
and a CIHR New Investigator Award. This work was supported by an NSERC Discovery grant
and by Canadian Institutes of Health Research, grant #SVB-145586, to PCB. The results
described here are in part based upon data generated by the ICGC/TCGA Pan-Cancer Analysis
of Whole Genomes Network: https://dcc.icgc.org/

341

Author Contributions

342
343
344

CHL and PCB initiated the project. CHL, SDP, RXS, FY and NS analyzed data. PCB supervised
research. CHL and PCB wrote the first draft of the manuscript, which all authors edited and
approved. The PCAWG network provided variant calls and insightful commentary.

Page 9 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

345

References (Main Text)

346

1. Cook, M. B. et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol.

347

Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 18, 1174â€“

348

1182 (2009).

349
350

2. Edgren, G., Liang, L., Adami, H.-O. & Chang, E. T. Enigmatic sex disparities in cancer
incidence. Eur. J. Epidemiol. 27, 187â€“196 (2012).

351

3. Cook, M. B., McGlynn, K. A., Devesa, S. S., Freedman, N. D. & Anderson, W. F. Sex

352

Disparities in Cancer Mortality and Survival. Cancer Epidemiol. Biomarkers Prev. 20, 1629â€“

353

1637 (2011).

354

4. Wichmann, M. W., Muller, C., Hornung, H. M., Lau-Werner, U. & Schildberg, F. W. Gender

355

differences in long-term survival of patients with colorectal cancer. Br. J. Surg. 88, 1092â€“1098

356

(2001).

357
358
359
360
361
362
363
364
365
366
367
368

5. Elsaleh, H. et al. Association of tumour site and sex with survival benefit from adjuvant
chemotherapy in colorectal cancer. Lancet Lond. Engl. 355, 1745â€“1750 (2000).
6. OuYang, P.-Y. et al. The significant survival advantage of female sex in nasopharyngeal
carcinoma: a propensity-matched analysis. Br. J. Cancer 112, 1554â€“1561 (2015).
7. Gupta, S., Artomov, M., Goggins, W., Daly, M. & Tsao, H. Gender Disparity and Mutation
Burden in Metastatic Melanoma. J. Natl. Cancer Inst. 107, djv221 (2015).
8. Sun, T., Plutynski, A., Ward, S. & Rubin, J. B. An integrative view on sex differences in brain
tumors. Cellular and Molecular Life Sciences 72, 3323â€“3342 (2015).
9. Dunford, A. et al. Tumor-suppressor genes that escape from X-inactivation contribute to
cancer sex bias. Nat. Genet. (2016). doi:10.1038/ng.3726
10. Yuan, Y. et al. Comprehensive Characterization of Molecular Differences in Cancer between
Male and Female Patients. Cancer Cell 29, 711â€“722 (2016).

Page 10 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

369
370
371
372

11. Warrington, N. M. et al. The Cyclic AMP Pathway Is a Sex-Specific Modifier of Glioma Risk
in Type I Neurofibromatosis Patients. Cancer Res. 75, 16â€“21 (2015).
12. Li, C. H., Haider, S., Shiah, Y.-J., Thai, K. & Boutros, P. C. Sex Differences in Cancer Driver
Genes and Biomarkers. Cancer Res 78, 5527 (2018).

373

13. Lopes-Ramos, C. M. et al. Gene Regulatory Network Analysis Identifies Sex-Linked

374

Differences in Colon Cancer Drug Metabolism. Cancer Research 78, 5538â€“5547 (2018).

375

14. Campbell, P. J., Getz, G., Stuart, J. M., Korbel, J. O. & Stein, L. D. Pan-cancer analysis of

376
377
378
379
380
381
382

whole genomes. bioRxiv (2017). doi:10.1101/162784
15. Dunford, A. et al. Tumor-suppressor genes that escape from X-inactivation contribute to
cancer sex bias. Nature Genetics (2016). doi:10.1038/ng.3726
16. Sabarinathan, R. et al. The whole-genome panorama of cancer drivers. bioRxiv (2017).
doi:10.1101/190330
17. Liu, R. & Xing, M. TERT promoter mutations in thyroid cancer. Endocrine-Related Cancer
ERC-15-0533 (2016). doi:10.1530/ERC-15-0533

383

18. Qin, Y. et al. The inhibitory effects of deleted in liver cancer 1 gene on gallbladder cancer

384

growth through induction of cell cycle arrest and apoptosis: Deleted in liver cancer 1 in

385

gallbladder cancer. Journal of Gastroenterology and Hepatology 29, 964â€“972 (2014).

386
387
388
389
390
391
392
393

19. Nik-Zainal, S. et al. Mutational Processes Molding the Genomes of 21 Breast Cancers. Cell
149, 979â€“993 (2012).
20. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500,
415â€“421 (2013).
21. Alexandrov, L. et al. The Repertoire of Mutational Signatures in Human Cancer. (2018).
doi:10.1101/322859
22. Cho, A., Chang, Y., Ahn, J., Shin, H. & Ryu, S. Cigarette smoking and thyroid cancer risk: a
cohort study. British Journal of Cancer 119, 638â€“645 (2018).

Page 11 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

394
395
396
397

23. Yeo, I.-K. & Johnson, R. A. A New Family of Power Transformations to Improve Normality or
Symmetry. Biometrika 87, 954â€“959 (2000).
24. Pâ€™ng, C. et al. BPG: Seamless, automated and interactive visualization of scientific data. BMC
Bioinformatics 20, (2019).

398
399

Page 12 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

400

Figures

401

Figures 1-4

402
403
404
405
406
407
408
409
410
411
412

Figure 1 | Sex biases in mutation frequency of driver genes, mutation prevalence and
tumour evolution. (a) From top to bottom, each plot shows the logistic regression q-value for the
sex effect; difference in proportion of mutated samples between the sexes, where blue denotes
male-bias and pink denotes female-bias; and mutation proportion for each gene. Bottom covariate
bars indicate mutation context and tumour subtype of interest. (b) The burden of somatic SNVs
for coding, non-coding and overall mutation load. Linear regression q-values are shown. (c)
Coding mutation load for thyroid adenocarcinoma samples compared by sex and presence or
absence of TERT promoter mutations. (d) The proportion of polyclonal samples and (e) the
proportion of truncal structural variants in biliary cancer.

Page 13 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

413

414
415
416
417
418
419
420
421
422
423
424
425
426
427

Figure 2 | Sex-biases in percent chromosome altered are reflected in gene-specific events.
(a) Dotmap showing association between sex and percent genome or chromosome altered,
where dot size shows difference in median percent genome/chromosome altered between the
sexes, and background shading shows q-values from linear regression. Sex differences in CNAs
for (b) pan-cancer, (c) kidney renal cell cancer and (d) hepatocellular cancer. Each plot shows,
from top to bottom: the q-value showing significance of sex from multivariate linear modeling with
yellow (green) points corresponding to 0.1 < q < 0.05 and deep blue (red) points corresponding
to q < 0.05; the proportion of samples with aberration; the difference in proportion between male
and female groups for copy number gain events; the same repeated for copy number loss events;
and the copy number aberration (CNA) profile heatmap. The columns represent genes ordered
by chromosome. Light blue and pink points represent data for male- and female- derived samples
respectively.
Page 14 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

428
429
430
431
432
433
434

Figure 3 | Sex differences in trinucleotide signatures related to mutational processes.
Comparisons between proportion of signature positive samples shown in barcharts and proportion
of attributed mutations shown in boxplots for (a) pan-cancer comparisons, (b) liver hepatocellular
cancer, and (c) B-cell non-Hodgkin lymphoma. FDR-adjusted q-values for logistic regression
(barplots) and linear regression (boxplots) shown only for significant comparisons. Blue shows
male- and pink shows female-derived samples.
Page 15 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

435
436
437
438
439
440
441
442
443

Figure 4 | The landscape of sex differences in cancer genomics. Heatmap shows genomic
features found to be sex-biased in pan-cancer analysis or in specific tumour subtypes. Results
from both PCAWG and TCGA analyses are shown. Direction of sex-bias is shown in coloration
denoting which sex has higher or more frequent aberration of the genomic feature. Top barplot
shows union of genes found to be involved in sex-biased CNAs. Starred indicate findings
exclusively from exome sequencing data (n=7,131) and unstarred indicate findings from PCAWG
data (n=1,983).

444

Page 16 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

445

Online Methods

446

Data acquisition & Processing

447
448
449

Data was downloaded from the PCAWG consortium through Synapse. All data pre-processing
was performed by the consortium as described14. Additional data-specific details are described
below.

450
451
452
453
454
455
456
457
458
459
460
461
462
463

General Statistical Framework
We followed a statistical approach as previously described in our previous work (Li et al). Briefly,
for each genomic feature of interest, we used univariate tests first followed by false discovery rate
(FDR) adjustment to identify putative sex-biases of interest (q < 0.1). Here, we use non-parametric
univariate tests to minimize assumptions on the data. For putative sex-biases, we then follow up
the univariate analysis with multivariate modeling to account for potential confounders using
bespoke models for each tumour subtype. Model variables for each tumour context are described
in Supplementary Table 1 and were included based on availability of data (<15% missing),
sufficient variability (at least two levels) and collinearity. Discrete data was modeled using logistic
regression. Continuous data was first transformed using the Box-Cox family and modeled using
linear regression. The Box-Cox family of transformations is a formalized method to select a power
transformation to better approximate a normal-like distribution and stabilize variance. We used
the Yeo-Johnson extension to the Box-Cox transformation that allows for zeros and negative
values23:
(ð‘¦ð‘– + 1)ðœ† âˆ’ 1
,
ðœ†
log(ð‘¦ð‘– + 1) ,
ð‘¦ð‘–ðœ† =
(âˆ’ð‘¦ð‘– + 1)2âˆ’ðœ† âˆ’ 1
âˆ’
,
2âˆ’ðœ†
{ âˆ’ log(âˆ’ð‘¦ð‘– + 1) ,

464

ð‘–ð‘“ ðœ† â‰  0, ð‘¦ â‰¥ 0
ð‘–ð‘“ðœ† = 0, ð‘¦ â‰¥ 0
ð‘–ð‘“ ðœ† â‰  2, ð‘¦ < 0
ð‘–ð‘“ ðœ† = 2, ð‘¦ < 0

465
466
467

FDR adjustment was performed for p-values for the sex variable significance estimate and an
FDR threshold of 10% was used to determine statistical significance. More detail is provided for
each analysis below.

468
469
470
471
472
473
474
475

Driver Event Analysis
We focused on driver events described by the PCAWG consortium16. Driver mutation data was
binarized to indicate presence or absence of the driver event in each patient. Proportions of
mutated genes were compared between the sexes using proportions tests for univariate analysis.
A q-value threshold of 0.1 was used to select genes for further multivariate analysis using binary
logistic regression. FDR correction was again applied and genes with significant pan-cancer sex
terms were extracted from the models (q-value < 0.1). Driver event analysis was performed
separately for pan-cancer analysis and for each tumour subtype.

Page 17 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

476

Clonal structure and mutation timing analysis

477
478
479
480
481
482
483
484

Subclonal structure and mutation timing calls were downloaded from Synapse
(https://www.synapse.org/#!Synapse:syn8532425). Subclonal structure data was binarized from
number of subclonal clusters per sample to monoclonal (one cluster) or polyclonal (more than
one cluster). The proportion of polyclonal samples was calculated per sex and compared using
proportion tests for both pan-cancer and tumour subtype analysis. The univariate p-values were
FDR adjusted across all tumour subtypes to identify putatively sex-biased clonal structure. These
cases were further scrutinized using logistic regression. A multivariate q-value threshold of 0.1
was used to determine statistically significant sex-biased clonal structure.

485

Mutation timing data classified SNVs, indels and SVs into clonal (truncal) or subclonal groups.

486

The proportion of truncal variants was calculated for each mutation type (

487
488
489
490
491
492

to obtain proportions of truncal SNVs, indels and SVs for each sample. These proportions were
compared between the sexes using two-sided Mann-Whitney U-tests and univariate p-values
were FDR adjusted to identify putatively sex-biased mutation timing. Linear regression was used
to adjust for confounding factors and a multivariate q-value threshold of 0.1 was used to determine
statistically significant sex-biased mutation timing. The mutation timing analysis was performed
separately for SNVs, indels and SVs.

493

Mutation Load analysis

494
495
496
497
498
499
500
501
502
503

Consensus
SNV
calls
were
downloaded
from
Synapse
(https://www.synapse.org/#!Synapse:syn7118450). Overall mutation prevalence per patient was
calculated as the sum of SNVs across all genes on the autosomes and scaled to mutations/Mbp.
Coding mutation prevalence only considers the coding regions of the genome, and noncoding
prevalence only considers the noncoding regions. Mutation load was compared between the
sexes using Mann-Whitney U-tests for both pan-cancer and tumour-type specific analysis.
Comparisons with u-test q-values meeting an FDR threshold of 10% were further analyzed using
linear regression to adjust for tumour subtype-specific variables. Mutation load analysis was
performed separately for each mutation context, with pan-cancer and tumour subtype p-values
adjusted together

504
505
506
507
508
509
510
511
512
513
514
515
516

Chromosome and Genome Instability analysis

ð‘ð‘¢ð‘šð‘ð‘’ð‘Ÿ ð‘¡ð‘Ÿð‘¢ð‘›ð‘ð‘Žð‘™ ð‘†ð‘ð‘‰ð‘ 
,
ð‘¡ð‘œð‘¡ð‘Žð‘™ ð‘†ð‘ð‘‰ð‘ 

etc)

Consensus
copy
number
data
was
obtained
from
Synapse
(https://www.synapse.org/#!Synapse:syn8042880). Ploidy-adjusted calls were used to identify
segments with copy number gains and losses. The number of bases in copy number gained or
lost segments were summed per chromosome and divided by chromosome size to obtain percent
chromosome gained and lost, respectively. All segments affected by a copy number aberration
were also summed and treated in the same way to calculate percent chromosome altered.
Percent copy number gained, lost, and altered were also calculated over the autosomes. These
metrics were compared in pan-cancer and tumour-subtype analysis using u-tests to identify
putatively sex-biased chromosome and genome instability, and putatively sex-biased events were
further analysed using linear regression modeling. Genome instability analysis was performed
separately for each tumour subtype with FDR adjustment performed over percent copy gained,
loss and altered comparisons together.
Page 18 of 19

bioRxiv preprint doi: https://doi.org/10.1101/528968; this version posted January 28, 2019. The copyright holder for this preprint (which was not
certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under
aCC-BY-ND 4.0 International license.

517

Genome-spanning CNA analysis

518
519
520
521
522
523
524

Consensus copy number data was processed to gain/neutral/loss calls per gene. The number of
loss, neutral and gain calls were summed per sex, and assessed using univariate and multivariate
techniques. For univariate analysis, proportional differences between the sexes for gains and
losses were tested for each gene using proportions tests. After identifying candidate pan-cancer
univariately significant genes, multivariate logistic regression was used to adjust ternary CNA data
for sex, age, ancestry and tumour-type. The genome-spanning analysis was performed
separately for losses and gains for each tumour subtype.

525

Mutational Signatures analysis

526
527
528
529
530

The number of mutations attributed to each SBS, DBS and ID signature per sample was
downloaded from Synapse (https://www.synapse.org/#!Synapse:syn8366024). For each
signature, we compared the proportion of samples with any mutations attributed to the signatures
(â€œsignature-positiveâ€) using Ï‡2-square tests to identify univariately significant sex-biases.
Signatures with putative sex-biases were further analysed using logistic regression.

531
532
533
534
535

We also compared the proportions of mutations attributed to each signature. The numbers of
mutations per signature were divided by total number of mutations for each sample to obtain the
proportion of mutations attributed to the signature. Mann-Whitney U-tests were used to compare
these proportions. Putative sex-biased signatures were further analysed using linear regression
after Box-cox adjustment.

536
537
538

Signatures that were not detected in a tumour subtype was omitted from analysis for that tumour
subtype. Statistical analyses were performed for each set tumour subtype, but combining all SBS,
DBS and ID signatures.

539
540
541

Statistical Analysis & Data Visualization
All statistical analyses and data visualization were performed in the R statistical environment
(v3.4.3) using the BPG24 (v5.9.8), car (v3.0-2) and mlogit (v0.2-4), packages.

Page 19 of 19

